Business
LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
LOS ANGELES, CA - January 23, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone canc...
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"text","content":"LOS ANGELES, CA - January 23, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target.","length":436,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise","length":119,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":352,"olType":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1293,"height":507,"url":"https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VCVJ6yC337nqarY7rX_X7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MmFuzfq1hlGGX6FrBtdqXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDI7Y2Y9d2VicA--/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":1200,"height":471}}},{"type":"text","content":"LIXTE's platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A ("PP2A"). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective","length":310,"tagName":"p"},{"type":"text","content":"Read More","length":9,"tagName":"p"},{"type":"text","content":"Please see full terms of use and disclaimers on the Investo...